IP Verse

An Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Disorder In Feline Animals

Patent No. EP3862003 (titled "An Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Disorder In Feline Animals") was filed by Boehringer Ingelheim on Dec 15, 2014. The application was issued on Oct 25, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ELANCOJul 24, 2024MURGITROYD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3862003

BOEHRINGER INGELHEIM
Application Number
EP21155065A
Filing Date
Dec 15, 2014
Status
Granted And Under Opposition
Sep 22, 2023
Publication Date
Oct 25, 2023
External Links
Slate, Register , Google Patents